Immunotherapy in Acute Leukemias
- 12 June 2024
- book chapter
- Published by Nobel Tip Kitabevleri
- p. 61-89
Abstract
Immunotherapeutic agents have made remarkable progress in the treatment of acute leukemia. CAR T cell therapy, particularly CD19 and BCMA-targeted CAR-T cells, has shown promising results with high response rates and long remission durations. However, these therapies can be challenging to manage and may present serious toxicities, requiring careful monitoring. Despite the challenges in AML CAR-T cell therapy, new approaches targeting CD33, CD123, and other antigens hold potential for effective treatment options in these patients. In ALL, anti-CD19, anti-CD22 agents, and even CAR-T cell therapies have started to find their place in practical use. With these developments, the integration of immunotherapies into personalized treatment plans is beginning to open new horizons in leukemia treatment.Keywords
This publication has 25 references indexed in Scilit:
- Sutimlimab in Cold Agglutinin DiseaseNew England Journal of Medicine, 2021
- Warm Autoimmune Hemolytic AnemiaNew England Journal of Medicine, 2019
- Atypical Hemolytic‐Uremic Syndrome: An Update on Pathophysiology, Diagnosis, and TreatmentTherapeutic Apheresis and Dialysis, 2018
- Current and emerging treatment options for autoimmune hemolytic anemiaExpert Review of Clinical Immunology, 2018
- Aplastic Anemia2018
- Paroxysmal Cold HemoglobinuriaHematology/Oncology Clinics of North America, 2015
- The diagnosis and treatment of aplastic anemia: a reviewInternational Journal of Hematology, 2015
- Novel immunotherapies for hematologic malignanciesImmunological Reviews, 2014
- Diagnosis and treatment of cold agglutinin mediated autoimmune hemolytic anemiaBlood Reviews, 2012
- Deficiency of the GPI anchor caused by a somatic mutation of the PIG-A gene in paroxysmal nocturnal hemoglobinuriaCell, 1993